Skip to main content
SpringerLink
Log in
Book cover

Klinische Neurologie pp 1–14Cite as

Gliome

  • 238 Accesses

Part of the book series: Springer Reference Medizin ((SRM))

Zusammenfassung

Gliome repräsentieren etwas mehr als ein Drittel aller primären Hirntumoren. Dazu gehören Astrozytome, Oligodendrogliome und die Ependymome. Glioblastome als bösartigste Variante astrozytärer Gliome sind am häufigsten. Gliome werden nach ihrem biologischen Verhalten und nach ihrer Histopathologie entsprechend der WHO-Klassifikation in die Malignitätsgrade I–IV eingeteilt. Diese Gradierung besitzt große prognostische Bedeutung. Die molekularen Parameter IDH1/2-Mutationsstatus und 1p/19q-Kodeletion helfen bei astrozytären und oligodendroglialen Tumoren bei der Planung der Chemotherapie.

This is a preview of subscription content, log in via an institution.

Literatur

  • Baumert BG et al (2016) Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17(11):1521–1532. https://doi.org/10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bent MJ van den et al (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366(9490):985–990

    Google Scholar 

  • Bent MJ van den et al (2006) Adjuvant Procarbazine, Lomustine, and Vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol 24:2715–2722

    Google Scholar 

  • Bent MJ van den et al (2012) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31(3):344–350. https://doi.org/10.1200/JCO.2012.43.2229. Epub 2012 Oct 15

    Article  CAS  PubMed  Google Scholar 

  • Bent MJ van den et al (2017) Interim results from the CATNON trial (EORTC study 26053–22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 390(10103):1645-1653. https://doi.org/10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8

    Article  CAS  Google Scholar 

  • Buckner JC et al (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 374(14):1344–1355. https://doi.org/10.1056/NEJMoa1500925

    Article  CAS  PubMed  Google Scholar 

  • Cairncross G et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24:2707–2714

    Article  CAS  PubMed  Google Scholar 

  • Cairncross G et al (2012) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31(3):337–343. https://doi.org/10.1200/JCO.2012.43.2674. Epub 2012 Oct 15

    Article  CAS  PubMed  Google Scholar 

  • Cavanee KP (2000) World Health Organization classification of tumours. Pathology and genetics.Tumours of the nervous system. IARC Press, Lyon

    Google Scholar 

  • Chinot OL et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722. https://doi.org/10.1056/NEJMoa1308345.2014

  • Combs SE et al (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863–8869

    Article  PubMed  Google Scholar 

  • Ewelt C et al (2011) Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence. Clin Neurol Neurosurg 113(7):541–547. https://doi.org/10.1016/j.clineuro.2011.03.008. Epub 2011 Apr 20 PMID: 21507562

    Article  PubMed  Google Scholar 

  • Friedman H et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740

    Article  CAS  PubMed  Google Scholar 

  • Gilbert MR et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708. https://doi.org/10.1056/NEJMoa1308573

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Glas M et al (2009) Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 27(8):1257–1261. https://doi.org/10.1200/JCO.2008.19.2195. Epub 2009 Feb 2. JCO 2009

    Article  CAS  PubMed  Google Scholar 

  • Glas M et al (2011) NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 70(3):445–453. https://doi.org/10.1002/ana.22478. Epub 2011 Jun 27

    Article  CAS  PubMed  Google Scholar 

  • Gnekow AK et al (2004) Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristine chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy – report from the multicenter treatment study for children and adolescents with a low grade glioma – HIT-LGG 1996 – of the Society of Pediatric Oncology and Hematology (GPOH). Klin Pädiatr 216:331–342

    Article  CAS  PubMed  Google Scholar 

  • Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241–248

    Article  PubMed  Google Scholar 

  • Hartmann C et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474

    Article  PubMed  Google Scholar 

  • Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003

    Article  CAS  PubMed  Google Scholar 

  • Herrlinger U (2016) Bevacizumab Plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. J Clin Oncol 34(14):1611–1619. https://doi.org/10.1200/JCO.2015.63.4691. Epub 2016 Mar 14

    Article  CAS  PubMed  Google Scholar 

  • Herrlinger U et al (2006) Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24(27):4412–4417

    Article  PubMed  Google Scholar 

  • Herrlinger U et al (2016) Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropath 131(2):309–319

    Article  CAS  PubMed  Google Scholar 

  • Herrlinger U et al (2019) Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393(10172):678–688. https://doi.org/10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14

    Article  CAS  Google Scholar 

  • Jalali R et al (2010) Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 77(1):113–118. https://doi.org/10.1016/j.ijrobp.2009.04.031. Epub 2009 Aug 3

    Article  CAS  PubMed  Google Scholar 

  • Jenkins RB et al (2006) A t(1,19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861

    Article  CAS  PubMed  Google Scholar 

  • Kaloshi G et al (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68(21):1831–1836

    Article  CAS  PubMed  Google Scholar 

  • Karremann M et al (2018) Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro-Oncology 20(1):123–131. https://doi.org/10.1093/neuonc/nox149

    Article  CAS  PubMed  Google Scholar 

  • Kreisl TN et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745

    Article  CAS  PubMed  Google Scholar 

  • Kunz M et al (2011) 2011 Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-Oncology 13(3):307–316. https://doi.org/10.1093/neuonc/noq196. Epub 2011 Feb 3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kurian KM et al (2005) Third ventricular chordoid glioma: clinicopathological study of two cases with evidence for a poor clinical outcome despite low grade histological features. Neuropathol Appl Neurobiol 31:354–361

    Article  CAS  PubMed  Google Scholar 

  • Leibel SA, Sheline GE (1987) Radiation therapy for neoplasms of the brain. J Neurosurg 66(1):1–22

    Article  CAS  PubMed  Google Scholar 

  • Louis DN et al (2007) World Health Organization classification of tumours. Pathology and genetics of tumours of the nervous system. The International Agency for Research on Cancer (IARC), 4. Aufl. IARC Press, Lyon

    Google Scholar 

  • Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1. Epub 2016 May 9

    Article  PubMed  Google Scholar 

  • Malmström A et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926. Epub 2012 Aug 8

    Article  PubMed  Google Scholar 

  • McGirt MJ et al (2008) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110(1):156–162

    Article  PubMed  Google Scholar 

  • Pajtler KW et al (2015) Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell 27(5):728–743. https://doi.org/10.1016/j.ccell.2015.04.002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Perry JR et al (2017) Mason WP; Trial Investigators. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med 376(11):1027–1037. https://doi.org/10.1056/NEJMoa1611977

    Article  CAS  PubMed  Google Scholar 

  • Pfister S (2008) 2008 BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 118(5):1739–1749. https://doi.org/10.1172/JCI33656

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111–126

    Article  CAS  PubMed  Google Scholar 

  • Roa W et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588

    Google Scholar 

  • Ross GW et al (1989) Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg 70(1):31–36

    Article  CAS  PubMed  Google Scholar 

  • Salazar OM et al (1983) Improved survival in cases of intracranial ependymoma after radiation therapy. Late report and recommendations. J Neurosurg 59(4):652–659

    Article  CAS  PubMed  Google Scholar 

  • Sethi J et al (2011) Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. Neurooncol 102(1):121–127. https://doi.org/10.1007/s11060-010-0301-y. Epub 2010 Jul 10

    Article  Google Scholar 

  • Smith JS et al (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26(8):1338–1345

    Article  PubMed  Google Scholar 

  • Stummer W et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401

    Article  CAS  PubMed  Google Scholar 

  • Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N Engl J Med 352:987–996

    Google Scholar 

  • Stupp R et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. https://doi.org/10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9

    Article  CAS  PubMed  Google Scholar 

  • Stupp R et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. A Randomized Clinical Trial JAMA 318(23):2306–2316. https://doi.org/10.1001/jama.2017.18718

    Article  CAS  PubMed  Google Scholar 

  • Vredenburgh JJ et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729

    Article  CAS  PubMed  Google Scholar 

  • Wick A et al (2009) Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256(5):734–741

    Article  CAS  PubMed  Google Scholar 

  • Wick W et al (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113–2115

    Article  CAS  PubMed  Google Scholar 

  • Wick W et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27(35):5874–5880

    Google Scholar 

  • Wick W et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. NOA 08 2012. Lancet Oncol 13(7):707–715. https://doi.org/10.1016/S1470-2045(12)70164-X. Epub 2012 May 10

    Article  CAS  PubMed  Google Scholar 

  • Wick W et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377:1954–1963. https://doi.org/10.1056/NEJMoa1707358

    Article  CAS  PubMed  Google Scholar 

  • Yan H et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yen CP et al (2006) Gamma knife surgery for metastatic brain stem tumors. J Neurosurg 105:213–219

    Article  PubMed  Google Scholar 

  • Yung WK et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17:2762–2771

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Klinische Neuroonkologie, Klinik und Poliklinik für Neurologie, Universitätsklinikum Essen, Essen, Deutschland

    Martin Glas & Sied Kebir

  2. DKFZ Abteilung Translationale Neuroonkologie am Westdeutschen Tumorzentrum, DKTK Partnerstandort Universitätsklinikum Essen, Essen, Deutschland

    Björn Scheffler

Authors
  1. Martin Glas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Björn Scheffler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sied Kebir
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Glas .

Editor information

Editors and Affiliations

  1. Deutsche Gesellschaft für Neurologie, Berlin, Germany

    Peter Berlit

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Glas, M., Scheffler, B., Kebir, S. (2020). Gliome. In: Berlit, P. (eds) Klinische Neurologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44768-0_86-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-44768-0_86-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-44768-0

  • Online ISBN: 978-3-662-44768-0

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Gliome
    Published:
    23 May 2020

    DOI: https://doi.org/10.1007/978-3-662-44768-0_86-2

  2. Original

    Gliome
    Published:
    06 March 2019

    DOI: https://doi.org/10.1007/978-3-662-44768-0_86-1

Search

Navigation